Andreas Pahl PhD

Dr. Andreas Pahl has worked as CSO at Heidelberg Pharma since 2012 Design. In addition to the service area with the emphasis on in vivo pharmacology and bioanalytics conducts the R & D department with a focus on oncology and "antibody-drug conjugates". In 2008 he moved into the industry for the company Nycomed and headed in the field of early drug discovery to pre-clinical pharmacology with focus on inflammatory and autoimmune diseases. After a research stay with an EMBO Fellowship at the University of Paris, he moved to the Institute of Pharmacology and Toxicology, University of Erlangen. There he built a special working group on the field of inflammation research and habilitation about 2002. He also teaches as a professor of pharmacology and toxicology at the Friedrich-Alexander University Erlangen-Nuremberg. Andreas Pahl studied chemistry at the Technical University of Berlin and received his doctorate in 1993 in the field of Biochemistry.